Intellia Therapeutics (NTLA) Misses Q1 EPS by 86c

Intellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($1.96), $0.86 worse than the analyst estimate of ($1.10). Revenue for the quarter came in at $0 versus the consensus estimate of $8.54 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• SpaceX: New Street Research sees 22% upside from proposed IPO price
• UBS Starts Motilal Oswal Financial Services Ltd (MOFS:IN) at Buy
• Anterix Inc. (ATEX) Tops Q4 EPS by 152c